Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report

Hyun Kim; Mohammed Alshalalfa; Jean Hoffman-Censits; Costas D. Lallas; Elai Davicioni; Jianqing Lin; Ruth Birbe; Nicholas Erho; Jonathan Lehrer; Hussam Al Deen Ashab; Mandeep Takhar; Anders Olson; Lucia L.C. Lam; W. Kevin Kelly; Karen E. Knudsen; Chellappagounder Thangavel; Roland Seiler; Felix Y. Feng; Edward M. Schaeffer; Edouard J. Trabulsi; Leonard G. Gomella; Mark D. Hurwitz; Adam P. Dicker; Robert B. Den

doi:10.1016/j.eucr.2016.08.010

Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report

Hyun Kim, Mohammed Alshalalfa, Jean Hoffman-Censits, Costas D. Lallas, Elai Davicioni, Jianqing Lin, Ruth Birbe, Nicholas Erho, Jonathan Lehrer, Hussam Al Deen Ashab, Mandeep Takhar, Anders Olson, Lucia L.C. Lam, W. Kevin Kelly, Karen E. Knudsen, Chellappagounder Thangavel, Roland Seiler, Felix Y. Feng, Edward M. Schaeffer, Edouard J. TrabulsiLeonard G. Gomella, Mark D. Hurwitz, Adam P. Dicker, Robert B. Den

Research output: Contribution to journal › Article › peer-review

Abstract

Management of men with prostate cancer is fraught with uncertainty as physicians and patients balance efficacy with potential toxicity and diminished quality of life. Utilization of genomics as a prognostic biomarker has improved the informed decision-making process by enabling more rationale treatment choices. Recently investigations have begun to determine whether genomic information from tumor transcriptome data can be used to impact clinical decision-making beyond prognosis. Here we discuss the potential of genomics to alter management of a patient who presented with high-risk prostate adenocarcinoma. We suggest that this information help selecting patients for advanced imaging, chemotherapies, or clinical trial.

Original language	English
Pages (from-to)	51-54
Number of pages	4
Journal	Urology Case Reports
Volume	9
DOIs	https://doi.org/10.1016/j.eucr.2016.08.010
State	Published - Nov 1 2016

Keywords

Genomics
Neuroendocrine
Prostate

Access to Document

10.1016/j.eucr.2016.08.010

Cite this

Kim, H., Alshalalfa, M., Hoffman-Censits, J., Lallas, C. D., Davicioni, E., Lin, J., Birbe, R., Erho, N., Lehrer, J., Ashab, H. A. D., Takhar, M., Olson, A., Lam, L. L. C., Kelly, W. K., Knudsen, K. E., Thangavel, C., Seiler, R., Feng, F. Y., Schaeffer, E. M., ... Den, R. B. (2016). Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report. Urology Case Reports, 9, 51-54. https://doi.org/10.1016/j.eucr.2016.08.010

@article{4d9c88ce1f7b4033b2960e3d06b0c85a,

title = "Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report",

abstract = "Management of men with prostate cancer is fraught with uncertainty as physicians and patients balance efficacy with potential toxicity and diminished quality of life. Utilization of genomics as a prognostic biomarker has improved the informed decision-making process by enabling more rationale treatment choices. Recently investigations have begun to determine whether genomic information from tumor transcriptome data can be used to impact clinical decision-making beyond prognosis. Here we discuss the potential of genomics to alter management of a patient who presented with high-risk prostate adenocarcinoma. We suggest that this information help selecting patients for advanced imaging, chemotherapies, or clinical trial.",

keywords = "Genomics, Neuroendocrine, Prostate",

author = "Hyun Kim and Mohammed Alshalalfa and Jean Hoffman-Censits and Lallas, {Costas D.} and Elai Davicioni and Jianqing Lin and Ruth Birbe and Nicholas Erho and Jonathan Lehrer and Ashab, {Hussam Al Deen} and Mandeep Takhar and Anders Olson and Lam, {Lucia L.C.} and Kelly, {W. Kevin} and Knudsen, {Karen E.} and Chellappagounder Thangavel and Roland Seiler and Feng, {Felix Y.} and Schaeffer, {Edward M.} and Trabulsi, {Edouard J.} and Gomella, {Leonard G.} and Hurwitz, {Mark D.} and Dicker, {Adam P.} and Den, {Robert B.}",

note = "Publisher Copyright: {\textcopyright} 2016",

year = "2016",

month = nov,

day = "1",

doi = "10.1016/j.eucr.2016.08.010",

language = "English",

volume = "9",

pages = "51--54",

journal = "Urology Case Reports",

issn = "2214-4420",

}

Kim, H, Alshalalfa, M, Hoffman-Censits, J, Lallas, CD, Davicioni, E, Lin, J, Birbe, R, Erho, N, Lehrer, J, Ashab, HAD, Takhar, M, Olson, A, Lam, LLC, Kelly, WK, Knudsen, KE, Thangavel, C, Seiler, R, Feng, FY, Schaeffer, EM, Trabulsi, EJ, Gomella, LG, Hurwitz, MD, Dicker, AP & Den, RB 2016, 'Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report', Urology Case Reports, vol. 9, pp. 51-54. https://doi.org/10.1016/j.eucr.2016.08.010

TY - JOUR

T1 - Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling

T2 - A Case Report

AU - Kim, Hyun

AU - Alshalalfa, Mohammed

AU - Hoffman-Censits, Jean

AU - Lallas, Costas D.

AU - Davicioni, Elai

AU - Lin, Jianqing

AU - Birbe, Ruth

AU - Erho, Nicholas

AU - Lehrer, Jonathan

AU - Ashab, Hussam Al Deen

AU - Takhar, Mandeep

AU - Olson, Anders

AU - Lam, Lucia L.C.

AU - Kelly, W. Kevin

AU - Knudsen, Karen E.

AU - Thangavel, Chellappagounder

AU - Seiler, Roland

AU - Feng, Felix Y.

AU - Schaeffer, Edward M.

AU - Trabulsi, Edouard J.

AU - Gomella, Leonard G.

AU - Hurwitz, Mark D.

AU - Dicker, Adam P.

AU - Den, Robert B.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Management of men with prostate cancer is fraught with uncertainty as physicians and patients balance efficacy with potential toxicity and diminished quality of life. Utilization of genomics as a prognostic biomarker has improved the informed decision-making process by enabling more rationale treatment choices. Recently investigations have begun to determine whether genomic information from tumor transcriptome data can be used to impact clinical decision-making beyond prognosis. Here we discuss the potential of genomics to alter management of a patient who presented with high-risk prostate adenocarcinoma. We suggest that this information help selecting patients for advanced imaging, chemotherapies, or clinical trial.

AB - Management of men with prostate cancer is fraught with uncertainty as physicians and patients balance efficacy with potential toxicity and diminished quality of life. Utilization of genomics as a prognostic biomarker has improved the informed decision-making process by enabling more rationale treatment choices. Recently investigations have begun to determine whether genomic information from tumor transcriptome data can be used to impact clinical decision-making beyond prognosis. Here we discuss the potential of genomics to alter management of a patient who presented with high-risk prostate adenocarcinoma. We suggest that this information help selecting patients for advanced imaging, chemotherapies, or clinical trial.

KW - Genomics

KW - Neuroendocrine

KW - Prostate

UR - http://www.scopus.com/inward/record.url?scp=84988980086&partnerID=8YFLogxK

U2 - 10.1016/j.eucr.2016.08.010

DO - 10.1016/j.eucr.2016.08.010

M3 - Article

C2 - 27713863

AN - SCOPUS:84988980086

SN - 2214-4420

VL - 9

SP - 51

EP - 54

JO - Urology Case Reports

JF - Urology Case Reports

ER -

Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this